Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

Last updated: April 8, 2025
Sponsor: M.D. Anderson Cancer Center
Overall Status: Active - Recruiting

Phase

2

Condition

Marginal Zone Lymphoma

Lymphoma, B-cell

Hematologic Cancer

Treatment

Bortezomib

Vincristine Sulfate Liposome

Etoposide

Clinical Study ID

NCT03136146
2016-0211
NCI-2018-01198
2016-0211
  • Ages > 15
  • All Genders

Study Summary

This phase II trial studies the side effects and how well combination chemotherapy works in treating patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, Burkitt lymphoma/leukemia, or double-hit lymphoma/leukemia that has come back or does not respond to treatment. Drugs used in chemotherapy, such as clofarabine, etoposide, cyclophosphamide, vincristine sulfate liposome, dexamethasone and bortezomib, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Relapsed/refractory acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL):

  • Relapsed and/or refractory Philadelphia negative acute lymphoblastic leukemiaor lymphoblastic lymphoma (LL) (Lead-in and Phase II)

  • Relapsed and/or refractory Philadelphia positive acute lymphoblastic leukemia,Burkitt leukemia/lymphoma or "double-hit" leukemia/lymphoma (phase II only)

  • At least 21 days elapsed from prior systemic chemotherapy (at least 14 days elapsedfrom prior systemic chemotherapy in the setting of rapidly progressive diseasewithout significant residual extramedullary toxicity). Hydroxyurea and dexamethasonepermitted up to approximately 24 hours prior to the start of therapy. Interruptionof tyrosine kinase inhibitor (TKI) not required in Ph positive ALL subset

  • Age older than 15 years

  • Eastern Cooperative Oncology Group (ECOG) performance status =< 3 (There may becertain patients with performance status [PS] 3 in the context of rapidlyproliferative/refractory ALL who would benefit from this regimen. We don't want toexclude such patients who may derive benefit from this salvage regimen)

  • Serum bilirubin =< 1.5 mg/dL

  • Serum glutamate pyruvate transaminase (SGPT) =< 3 x upper limit normal (ULN), withexception for Gilbert's syndrome

  • Estimated creatinine clearance or GFR (glomerular filtration rate) >= 50 mL/min

  • Signed informed consent

Exclusion

Exclusion Criteria:

  • Active >= grade 3 peripheral neuropathy

  • Active hepatic graft-versus-host disease

  • Known positivity for hepatitis B or C

  • Pregnancy

  • Breast feeding

Study Design

Total Participants: 42
Treatment Group(s): 9
Primary Treatment: Bortezomib
Phase: 2
Study Start date:
August 09, 2017
Estimated Completion Date:
August 01, 2026

Study Description

PRIMARY OBJECTIVE:

I. To collect the safety/toxicity information and assess the initial efficacy information (objective overall response rate: complete response [CR]+ CR with incomplete platelet recovery [CRp]/CR with incomplete bone marrow recovery [CRi]) after treatment with clofarabine, etoposide, cyclophosphamide (CEC), vincristine sulfate liposome (liposomal vincristine) (VCR), dexamethasone and bortezomib in relapsed/refractory acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL) including relapsed/refractory Philadelphia (Ph) positive B-ALL/LL or Burkitt's leukemia/lymphoma or double-hit leukemia/lymphoma.

SECONDARY OBJECTIVE:

I. To determine the CR duration, event free survival (EFS), and overall survival (OS) after treatment with CEC, liposomal VCR, dexamethasone and bortezomib in relapsed/refractory ALL or LL including relapsed/refractory Ph positive B-ALL/LL or Burkitt's leukemia/lymphoma or double-hit leukemia/lymphoma.

OUTLINE:

INDUCTION: Patients receive clofarabine intravenously (IV) over 1-2 hours on days 1-5, etoposide IV over 2 hours on days 1-5, cyclophosphamide IV over 1 hour on days 1-5, vincristine sulfate liposome IV over 1 hour on days 2 and 11, dexamethasone orally (PO) daily or IV over 15 minutes on days 1-5, bortezomib subcutaneously (SC) on days 1, 4, 8 and 11, ofatumumab or rituximab IV over 4-24 hours on days 2 and 11, and pegfilgrastim SC on day 6 in the absence of disease progression or unacceptable toxicity. Patients may receive 1 additional course of induction therapy depending on the disease response.

CONSOLIDATION THERAPY: Patients receive clofarabine IV over 1-2 hours on days 1-4, etoposide IV over 2 hours on days 1-4, cyclophosphamide IV over 1 hour on days 1-4, vincristine sulfate liposome IV over 1 hour on days 2 and 11, dexamethasone PO or IV over 15 minutes on days 1-5, bortezomib SC on days 1, 4, 8 and 11, pegfilgrastim SC on day 6. Treatment repeats every 28 days for up to 5 courses in the absence of disease progression or unacceptable toxicity. Patients may receive ofatumumab or rituximab IV over 4-24 hours on days 2 and 11 for 4 courses.

Connect with a study center

  • M D Anderson Cancer Center

    Houston, Texas 77030
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.